GlassScriptPhysician profile
Leo Edward Reap
NPI 1568844082
$4,325.71
in general payments reported to CMS, 2019-2025
33 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $573 · 2021: $209 · 2022: $169 · 2023: $674 · 2024: $345 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588 · Long Term Medical Supply Or Device Loan: $698 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.67 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $307.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,346.62 | 2019-2025 | |
| Gilead Sciences, INC. | $685.91 | 2022-2025 | Trodelvy |
| Genentech USA, INC. | $370.16 | 2020-2025 | Polivy |
| Kite Pharma, INC. | $284.87 | 2019-2024 | Yescarta |
| Janssen Biotech, INC. | $271.69 | 2021-2024 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $258.68 | 2019-2025 | Opdualag, Opdivo |
| Abbvie INC. | $191.97 | 2019-2025 | |
| Incyte Corporation | $125.04 | 2020 | |
| Astellas Pharma US INC | $113.72 | 2019-2024 | Xtandi |
| Eisai INC. | $63.34 | 2019 | |
| Amgen INC. | $63.13 | 2019 | |
| Celgene Corporation | $62.94 | 2019-2025 | Reblozyl |
| Emd Serono, INC. | $42.15 | 2024 | |
| Aveo Pharmaceuticals, INC. | $33.96 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $33.57 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.21 | 2025 | Blenrep, Ojjaara |
| Tersera Therapeutics LLC | $32.44 | 2019-2025 | Zoladex |
| Recordati_rare_diseases_inc. | $32.00 | 2025 | Enjaymo |
| Merck Sharp & Dohme LLC | $30.18 | 2019 | |
| Genmab U.S., INC. | $28.16 | 2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $23.33 | 2019 | |
| Pfizer INC. | $23.00 | 2025 | |
| Agios Pharmaceuticals, INC. | $22.20 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.47 | 2025 | |
| Tempus Ai, INC | $20.33 | 2025 | Xt Cdx |
| Taiho Oncology, INC. | $19.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2025 | Vpriv |
| Array Biopharma INC | $17.09 | 2025 | Mektovi, Braftovi, Xalkori |
| Regeneron Healthcare Solutions, INC. | $16.68 | 2025 | Libtayo |
| Sobi, INC | $16.56 | 2025 | |
| Puma Biotechnology, INC. | $13.60 | 2019 | |
| Genzyme Corporation | $11.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Reap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.